About George Scangos
George Scangos is a director at Voyager Therapeutics.
Form D filings name George Scangos as a director at Encentrio Therapeutics.
George Scangos reports to the SEC as a director or officer of 6 public companies, including Agilent Technologies (A), Vir Biotechnology (VIR) and Exelixis (EXEL).
George Scangos first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name George Scangos in the role, so the role may have started earlier or lasted longer.
VI
Voyager Therapeutics, Inc.
Director
2023 – 2026 · Public company (VYGR)
AI
Agilent Technologies, Inc.
Director
2014 – 2026 · Public company (A)
VI
Vir Biotechnology, Inc.
President and CEO, director
2019 – 2025 · Public company (VIR)
EI
Exelixis, Inc.
President & CEO, director
2006 – 2020 · Public company (EXEL)
BI
Biogen Inc.
Chief Executive Officer and director
2010 – 2016 · Public company (BIIB)
AI
Anadys Pharmaceuticals Inc.
Director
2006 – 2010 · Public company (ANDS)
Key Colleagues at Startups
The people George Scangos works with at each company, as listed on that company's latest Form D.
Encentrio Therapeutics, Inc. · Form D, Apr 3, 2023
TH
Thomas Hecht
Director
SL
Sung Lee
Executive officer and director
JN
Johanna Friedl-Naderer
Director
NS
Natascha Schill
Chief Executive Officer and director
VV
Vanina de Verneuil
Executive officer